NASDAQ · TNXP

Tonix Pharmaceuticals Holding Corp.

$10.12 +$0.24 (+2.43%) 1D Market open

Key Metrics

$157.50M
Market cap
P/E · TTM
$17.56M
Revenue · TTM
−$147.39M
Net income
EPS · TTM $-24.87
Dividend yield
Free cash flow −$130.64M
Beta · 1Y 2.41
EBITDA · TTM −$149.20M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Jan 30 high, the share price fell 43%.

    Peak close $17.24 on Jan 30; trough close $9.88 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -43%
  • Jul 21
    A material event was filed (Form 8-K).

    8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 15
    The stock moved +11.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 15
  • Mar 31
    The stock moved +14.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 31

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$157.50M
Enterprise value
Shares outstanding15.9M
52-wk range$9.81 – $69.97
Avg volume · 20D310.9K
Net cash
Book value / share$38.32
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Tonix Pharmaceuticals Holding Corp.
IPO dateFeb 13, 2009
Employees142

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S8.97
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -861.2%
Net -839.5%
FCF -744.1%
ROE / ROIC -80.4% · —

Financial Health

Current ratio6.99
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$177.52M

Cash Flow · TTM

Operating CF −$125.58M
Capex −$5.06M
Free cash flow −$130.64M
Buybacks $13.76M
Dividends paid
Shareholder yield 8.7%

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

-2.8
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings